AstraZeneca (NYSE:AZN) has been assigned a $40.00 price objective by stock analysts at BMO Capital Markets in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. BMO Capital Markets’ price target indicates a potential upside of 15.57% from the stock’s previous close.

Several other research analysts have also weighed in on AZN. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Monday. Jefferies Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and increased their price target for the company from $28.43 to $36.70 in a research report on Monday. Sanford C. Bernstein increased their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Finally, Leerink Swann increased their price target on shares of AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and a consensus target price of $36.32.

How to Become a New Pot Stock Millionaire

Shares of AstraZeneca stock remained flat at $$34.61 on Thursday. The stock had a trading volume of 2,776,167 shares, compared to its average volume of 4,060,953. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. AstraZeneca has a 12 month low of $28.43 and a 12 month high of $36.70. The company has a market capitalization of $88,068.80, a price-to-earnings ratio of 14.62, a price-to-earnings-growth ratio of 2.07 and a beta of 0.71.

AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The company had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same period in the prior year, the business posted $1.21 earnings per share. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. analysts expect that AstraZeneca will post 1.7 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $101,000. Valeo Financial Advisors LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $133,000. Delpha Capital Management LLC purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $152,000. Calton & Associates Inc. purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $181,000. Finally, Wealthcare Advisory Partners LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $184,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “AstraZeneca (AZN) PT Set at $40.00 by BMO Capital Markets” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/astrazeneca-azn-pt-set-at-40-00-by-bmo-capital-markets/1957406.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.